Dasolampanel
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C17H20ClN5O3 |
Molar mass | 377.83 g·mol−1 |
3D model (JSmol) | |
| |
|
Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by / for the treatment of chronic pain conditions including neuropathic pain and migraine.[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection,[2][3] but ultimately neither drug was ever marketed.
See also[]
References[]
- ^ Stolerman IP (31 July 2010). Encyclopedia of Psychopharmacology. Springer Science & Business Media. pp. 514–. ISBN 978-3-540-68698-9.
- ^ Olesen J, Ramadan N (21 August 2008). Innovative Drug Development for Headache Disorders. Oxford University Press. pp. 188–. ISBN 978-0-19-955276-4.
- ^ Firestein GS, Budd R, Gabriel SE, O'Dell JR, McInnes IB (31 August 2012). Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. pp. 1031–. ISBN 978-1-4557-3767-3.
Categories:
- Drugs not assigned an ATC code
- AMPA receptor antagonists
- Analgesics
- Antimigraine drugs
- Carboxylic acids
- Decahydroisoquinolines
- Kainate receptor antagonists
- Chlorobenzenes
- Prodrugs
- Tetrazoles
- Analgesic stubs